Pyoderma gangrenosum with plasma cell dyscrasia should be subject for anti-myeloma treatment Dear Editor, Pyoderma gangrenosum (PG) is a rare inflammatory disorder characterized by chronic and recurrent cutaneous ulcers.1 PG can be idiopathic or occur in association with other conditions.2 Approximately 21% of patients with PG have a co-occurrence of a hematological condition, 10% with plasma cell dyscrasia, like monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM).3 Both MGUS, a condition observed in 3.2% of individuals 50 years of age and older,4 and smoldering MM (SMM) in an asymptomatic pre-malignant stage with a 10% annual risk of progression, are associated with clonal plasma-cell proliferation and detectable monoclonal proteins (MP). Both achieved complete healing of the PG lesions during MM treatment, but the male MGUS patient relapsed, in PG, probably because of less aggressive treatment due to frailty and comorbidities. [Extracted from the article]